Federated Hermes
CGEM icon

Federated Hermes’s Cullinan Oncology CGEM Stock Holding History

Federated Hermes’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.07K Sell
388
-128
-25% -$1.9K ﹤0.01% 1881
2026
Q1 		$7.33K Buy
+516
New +$6.63K ﹤0.01% 1860
2025
Q3 		– Sell
-1,495
Closed -$11.3K – 2134
2025
Q2 		$11.3K Sell
1,495
-963
-39% -$7.74K ﹤0.01% 1804
2025
Q1 		$18.6K Sell
2,458
-1,344
-35% -$12.9K ﹤0.01% 1733
2024
Q4 		$46.3K Buy
3,802
+1,525
+67% +$21.9K ﹤0.01% 1684
2024
Q3 		$38.1K Buy
2,277
+2,116
+1,314% +$37.5K ﹤0.01% 1694
2024
Q2 		$2.81K Sell
161
-83
-34% -$1.77K ﹤0.01% 1883
2024
Q1 		$4.16K Buy
+244
New +$3.77K ﹤0.01% 1860
2023
Q4 		– Sell
-20,000
Closed -$181K – 2063
2023
Q3 		$181K Buy
+20,000
New +$208K ﹤0.01% 1538

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Federated Hermes's CGEM Position: Q2 2026 in Review

Federated Hermes reduced its Cullinan Oncology (CGEM) stake by 25% in Q2 2026, selling an estimated $1.9K and leaving 388 shares worth $7.07K. The position accounts for ﹤0.01% of the portfolio, ranked #1881.

Federated Hermes first reported a position in CGEM in Q3 2023 and has held it in 9 quarters since. The position peaked at $181K in Q3 2023. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Federated Hermes held 388 shares of Cullinan Oncology worth $7.07K as of Q2 2026.
  • Federated Hermes sold 128 Cullinan Oncology shares in Q2 2026, an estimated $1.9K.
  • Cullinan Oncology made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1881 holding.
  • Federated Hermes first reported a position in Cullinan Oncology in Q3 2023 and has held it in 9 quarters since.
  • Federated Hermes's Cullinan Oncology position peaked at $181K in Q3 2023.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.